Anticoagulation in chronic nonvalvular atrial fibrillation: A critical appraisal and meta-analysis

Canadian Journal of Cardiology

Volumn 13, Issue 9, 1997, Pages 811-815

  Green, Carolyn J ^a   Hadorn, David C ^a   Bassett, Ken ^a   Kazanjian, Arminée ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Anticoagulation; Atrial fibrillation; Meta analysis; Warfarin

Indexed keywords

WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEATH; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MEDICAL LITERATURE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBROVASCULAR DISORDERS; HUMANS; INCIDENCE; OUTCOME ASSESSMENT (HEALTH CARE); RESEARCH DESIGN; RISK FACTORS; WARFARIN;

EID: 0030775248     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. American College of Physicians. Guidelines for medical treatment for stroke prevention. Ann Intern Med 1994;121:54-5.
2. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest 1994;108(Suppl):352S-9S.
3. Kerr CR, Klein GJ. Atrial fibrillation - future directions. Can J Cardiol 1996;12(Suppl A):58A-61A.
4. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 1991;84:527-39.
5. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. Effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990;323:1506-11.
6. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:349-55.
7. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-12.
8. Peterson P, Boyson G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet 1989;i:175-9.
9. Hadorn DC, Baker D, Hodges JS, Hicks N. Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 1996;49:749-54.
10. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
11. Sisk C, Ziegler DK, Zileli T. Discrepancies in recorded results from duplicate neurological history and examination in patients studied for prognosis in cerebrovascular disease. Stroke 1970;1:14-8.
12. Tomasello F, Mariani F, Fieschi C, et al. Assessment of inter-observer differences in the Italian multicenter study on reversible cerebral ischemia. Stroke 1982;13:32-5.
13. Shinar D, Gross CR, Mohr JP, et al. Interobserver variability in the assessment of neurologic history and examination in the Stroke Data Bank. Arch Neurol 1985;42:557-65.
14. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
15. Green CJ, Hadom D, Kazanjian A. Anticoagulation for Stroke Prevention in Chronic Non-valvular Atrial Fibrillation. British Columbia Office of Health Technology Assessment Report 95:2T. Vancouver: University of British Columbia, 1995.
16. Fleiss JL. Statistical Methods for Rates and Proportions, 2nd edn. New York: John Wiley and Sons, 1981:160-87.
17. Cooper H, Hedges LV, eds. The Handbook of Research Synthesis. New York: Russell Sage Foundation, 1994:261-99.
18. Secondary and Tertiary Prevention of Stroke Parient Outcomes Research Team. Seventh Progress Report. Rockville: Department of Health and Human Services, Agency for Health Care Policy and Research, 1995.
19. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993,95:315-28.
20. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994;154:1945-53.
21. Singer DE. Problems with stopping rules in trials of risky therapies: the case of warfarin to prevent stroke in atrial fibrillation. Clin Res 1993;41:482-6.
22. Lip GY, Tean KN, Dunn FG. Treatment of atrial fibrillation in a district general hospital. Br Heart J 1994;71:92-5.
23. O'Hare JA, Ul-Iman N, Geoghegan M. Non-anticoagulation in atrial fibrillation. Ir J Med Sci 1994;163:448-50.
24. Alberts MJ, Dawson DV, Massey EW. A follow-up survey of clinical practices for the use of heparin, warfarin, and aspirin. Neurology 1994;44:618-21.
25. Dow L, Bertagne B. Underuse of warfarin is multifactorial. BMJ 1993;307:1492-3.
26. GPs slow to adopt best treatment for atrial fib. Med Post 1992;28:10.
27. McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett EL. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995;155:277-81.
28. Laupacis A, Sullivan K. Canadian Atrial Fibrillation Anticoagulation study: were the patients subsequently treated with warfarin? Can Med Assoc J 1996;154:1669-74.
29. Antani MR, Beyth RJ, Covinsky KE, et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med 1996;11:713-20.
30. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996;156:2537-41.
31. Boonen S, Wu A. Nonvalvular atrial fibrillation and primary stroke prevention from a geriatric point of view. Acta Clin Belg 1994;49:86-91.
32. Connolly SJ, Turpie AGG. Antithrombotic therapy in atrial fibrillation Can J Cardiol 1996;12(Suppl A):17A-20A.
33. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993;342:1255-62.